SpeeDx Establishes New European Subsidiary

SYDNEY, AUSTRALIA--(Marketwired - June 02, 2016) -

SpeeDx Pty. Ltd. announced today the establishment of a European subsidiary company, SpeeDx Limited, to be headquartered in the London Bioscience Innovation Centre. The UK-based headquarters will support the future launch of SpeeDx PlexPCR™ multiplex qPCR assays. SpeeDx has filed for CE-IVD Mark for PlexPCR™ HSV-1&2, VZV for the detection of three different types of herpes viruses and is finalising test submission for Mycoplasma genitalium, a newly-recognized sexually transmitted infection.

“We believe this new European presence is an essential step in supporting the launch of our clinical diagnostic products,” said Colin Denver, Vice President of Sales & Marketing for SpeeDx. “Our range of PlexPCR™ tests will help streamline infectious disease management for laboratories, while our future ResistancePlus™ portfolio can offer labs valuable information about antimicrobial resistance to ultimately influence treatment options.”

The SpeeDx technological advantage provides a single-test solution with information on both the causative agent of disease and the presence of antibiotic resistance markers. This important information is vital to maintaining effective treatment standards while supporting attempts to slow the rise of antibiotic resistance, a need clearly highlighted in the recent UK government review on antimicrobial resistance (AMR) published by Jim O’Neill.(1)

“We look forward to the opportunity to achieve a strong European presence in targeted molecular diagnostic markets,” said Terry Sunderland, European Sales Manager for SpeeDx. “The London Bioscience Innovation Centre is an ideal launching pad to support our distribution strategy in Europe and it is the perfect entry into the UK market.”

About PlexPCR™ and ResistancePlus™
PlexPCR™ and ResistancePlus™ constitute multiplex qPCR kits for detection of infectious disease pathogens and antimicrobial resistance markers, respectively. Powered by the company’s proprietary PlexZyme™ and PlexPrime™ technologies, both product lines offer high multiplexing capability for better, more streamlined infectious disease management. With increased ability to detect more pathogens as well as multiple genetic markers, every PlexPCR™ and ResistancePlus™ test provides more actionable information for laboratories and clinicians alike.

About SpeeDx
Based in Sydney, Australia and founded in 2009, SpeeDx is a privately owned company specializing in innovative multiplex real-time polymerase chain reaction (qPCR) solutions for clinical diagnostics. SpeeDx has a portfolio of market leading detection and priming technologies to enable new healthcare paradigms based on improved delivery and reduced costs. SpeeDx has a proven track record of scientific discovery and strives to provide cutting edge clinically relevant tools for the clinical diagnostic market. For more information on SpeeDx please see: http://www.speedx.com.au/

About the London Innovation Bioscience Centre
The London BioScience Innovation Centre (LBIC) provides a focus for life sciences activity in the UK capital, offering laboratory and office facilities of an exceptionally high standard. Owned by the prestigious Royal Veterinary College, LBIC is home to over 60 biotechnology and life science companies in central London.

1 Tackling drug-resistant infections globally: final report and recommendations - the review on antimicrobial resistance. May 19 2016.